Can Facet Arthroplasty Outperform TLIF for Spondy?

Key Takeaways

• TOPS achieved 85% composite clinical success vs 64% for TLIF
• ODI improvement ≥15 points in 93% of TOPS patients
• Motion preserved: 3.86° flexion‑extension ROM at 24 months
• Reoperation rate lower for TOPS (5.9%) than TLIF (8.8%)
• Long‑term adjacent‑segment impact remains unanswered beyond two years

Pulse Analysis

Degenerative lumbar spondylolisthesis has traditionally been treated with decompression plus fusion, most often via TLIF, because fusion offers immediate stability and predictable radiographic outcomes. However, fusion eliminates segmental motion, raising concerns about adjacent‑segment degeneration and loss of natural biomechanics. In recent years, motion‑preserving technologies such as posterior facet arthroplasty have emerged, promising to maintain physiological motion while still providing the necessary stability for symptomatic slips. \n\nThe FDA‑sponsored IDE trial led by Coric et al.

enrolled 170 patients in the TOPS arm and 79 in the TLIF arm, all with single‑level L4‑5 stenosis and grade I spondylolisthesis. The primary endpoint—composite clinical success—required no reoperations, no device failure, at least a 15‑point ODI improvement, and no new neurological deficit. TOPS met this stringent criterion in 85% of cases, a statistically significant 21‑point advantage over TLIF. Functional outcomes mirrored this trend, with 93% of TOPS patients achieving the ODI threshold versus 81% for TLIF, while back‑pain VAS improvements favored TOPS though without statistical significance. \n\nFor spine surgeons, these findings suggest that fusion may no longer be the universal default for grade I spondylolisthesis.

The combination of comparable safety, superior composite success, and preserved segmental kinematics positions posterior facet arthroplasty as a viable alternative, especially for patients where motion preservation could mitigate long‑term adjacent‑segment wear. Nonetheless, the trial’s 24‑month horizon leaves open questions about durability beyond the short term and the true impact on adjacent‑segment degeneration. Ongoing registries and longer follow‑up will be essential to confirm whether the early functional gains translate into reduced reoperation rates and sustained quality of life. As evidence accumulates, hospitals and device manufacturers may see a shift in reimbursement models and surgical training toward motion‑preserving solutions.